AU612837B2 - Creation of Inventions and Patents with Artificial Intelligence

AU612837B2 – Method for production of human tissue type plasminogen activator
– Google Patents

AU612837B2 – Method for production of human tissue type plasminogen activator
– Google Patents
Method for production of human tissue type plasminogen activator

Download PDF
Info

Publication number
AU612837B2

AU612837B2
AU34892/89A
AU3489289A
AU612837B2
AU 612837 B2
AU612837 B2
AU 612837B2
AU 34892/89 A
AU34892/89 A
AU 34892/89A
AU 3489289 A
AU3489289 A
AU 3489289A
AU 612837 B2
AU612837 B2
AU 612837B2
Authority
AU
Australia
Prior art keywords
tpa
medium
production
chain
cells
Prior art date
1988-05-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU34892/89A
Other versions

AU3489289A
(en

Inventor
Nobumi Kusuhara
Nobuyoshi Makiguchi
Shoichiro Miyahara
Atsunori Shindo
Maki Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mitsui Toatsu Chemicals Inc

Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-05-19
Filing date
1989-05-17
Publication date
1991-07-18

1988-05-19
Priority claimed from JP12264488A
external-priority
patent/JP2648611B2/en

1988-12-16
Priority claimed from JP63316118A
external-priority
patent/JP2718726B2/en

1989-05-17
Application filed by Mitsui Toatsu Chemicals Inc
filed
Critical
Mitsui Toatsu Chemicals Inc

1989-11-23
Publication of AU3489289A
publication
Critical
patent/AU3489289A/en

1991-07-18
Application granted
granted
Critical

1991-07-18
Publication of AU612837B2
publication
Critical
patent/AU612837B2/en

2009-05-17
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

C12N9/14—Hydrolases (3)

C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue

C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

C12N9/6424—Serine endopeptidases (3.4.21)

C12N9/6456—Plasminogen activators

C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

C12N5/0018—Culture media for cell or tissue culture

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12Y—ENZYMES

C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)

C12Y304/21—Serine endopeptidases (3.4.21)

C12Y304/21069—Protein C activated (3.4.21.69)

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2500/00—Specific components of cell culture medium

C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Abstract

A method for the production of human tissue type plasminogen activator (tPA) using cells includes use of a p-aminomethyl benzoic acid derivative to supplement a cell culture medium or a tPA producing medium and further an increase of osmotic pressure in the medium to 350 milliosmoles or more per litre. The method can produce single-chain tPA in a high concentration and with a relatively small amount of double-chain tPA in the medium.

Description

I c~ i
AUSTRALIA
Patents Act I 2 37 CCIMPLEME SPECIFICAICN
(ORIGINAL)
Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art:
IV
I; Appllcant(s): Httsu Toatsu Chemicals# [ncorporated Kasumloseddk 3-chome,, Chiyoda-kut, Address for Service iot Tokyo, JAPAN PUIIPS CMUME FI ZPARCI Patent and Trade M~r At ny 367 collins Street Helbourne 3000 AUSTRALIA Complete Specificton for the invention entitlodt “TI1D FOR PRODUCTION Or CIFUAN TISUH TYPH PLASHINOGEH ACTUATOR Our taef 152668 PF Code: 1566/1719 The fIollovi state~n sa. 4, fUIl1 descrption of this inventionp lncudlog the boet imithod of performino it known to plioat(s) 60069
I
i i I’ i! ;i i: ji C c i ii 4
SPECIFICATION
TITLE OF THE INVENTION METHOD FOR PRODUCTION OF HUMAN TISSUE TYPE PLASMINOGEN ACT IVATOR BACKGROUND OF THE I MVENT O 1. Field of the Invention.: This invention relates kn, a method for producing tissue type plasr-inogen activator (hereinafter referred to as tPA) produced by human normal cells.
tPA which is produced and excreted by vascular 10 endothelial cells and various tissue cells lyses fibrin clots, namoely thrombi4. Thus, tPA is effective as f-, do:% thrombOlytic agent.
2. Description of (the Prior Art tPA has two molecular forms.’, tlgecar PA and 0 C4 i double-chaln. VA. Thromboytic activity of double-chain tPA Is hIgher than that of sthngle-chain tPA* So-called tPA lhas been conventionally developed as the sole douible-chaln form or the otixture form of the doubte-chain and the single-chain form, Douhle-chain tPA hasi high tibrinolytic activity, and It to highly pooolble that double-chain tPA activates plasminogon not in thrombi Where flbirloolytic 0effec(-t is expected but In the blood stream# which often causes ‘4 clinical bleeding (Japanese Patent Laid-open Pub. No.
On the other hand, single-chain tPA which is considered to be a precursor of double-chain tPA has high aff ini ty to f ibrin and is quickly converted to double-chain tPA once bound to fibrin.
Accordingly, gingle-chain tPA maximally exhibits plasmninogeni activi ty At clotting si tes.
Thus, thrombolytic activity of single-chain tPA is relati vely low and not exhibi ted in the blood s tream. In consequence, for clinical use, single-chain tPA is In 0 0 gre4 ter demand than doublIe-cha in tPA, and on e f fec t ive 00 0 method for the production of single-chain tPA is highly 0 0 requested, However, in production of siogle-chain tPA using cells, 0 00 0 there is A Problem that pro teolytIc enZymes contained in a medium or produced by the Celts (mootly considered to be 0001410 0 lam o trypsln) convert slnegle-chain tPA to double-Chain tPAM during production processes, which interferes with effective Produc-tion Of Oinf~Ie-Ohain tPA.
Relevant mothocls Known to golve such problem altoe desncribed b~w They are a mothod In which cultivation and subsequent stea ae crried out in tile pvesence of aprotinin (irpea ?iPatent Pulica10tioo No, ‘ii7hO), a. nothod in which trypsio Inhibitor lnduced by tonyboann or aiprotin~oin 13 dded In the cul ture medium for tPA-producing eel s (Japanese ~n ‘Laid-open Pub, No. 118717/1984), a method in whichs cultivation or induction production is carried out in a medium supplemented with aprotinin or benzamidine (Japanese Patent Laid-Open Pub, No, 10,186/1986) and a method. in which sole single-chain tPA is produced by adding aprotinin or 6aminocapronic acid in a purificatton process (BIochemn, Biophys, Ac(a M10(), 318-328, 198Z), Furthermore, particularly in the case where adhesive cells are used, there is a difficult problem that the cells are detached from the wall of a container or the surface of P beads during cultivaton. To solve this problem, removal of OD 0 piasmiri from the serum and addition of’ aprotinin are suggested (IKAufrnan Molecular’ and Cellular Biology, k, 1s P0V70).
flowever, there are many difficufllies in practicing these eonvwsntlonal methods on industrial scale, lFor excample, arrottnln to used Is quite expeasive. And remoVo1l of plawmin from the serum. requires oompticated S 20 Processes.
jtE, _1Vr%_Tj__ In tthe course of IntonialVo otudy to solVo problema of the abovemnentlonod known mothods for the produatlan of tPA, the present Invontor. havQ found thait to WA production 2 0) by 001la, p~tclryby adhesivo coll”# It is effective to addt p-.ainomthyl honzolc AcId derIVAtLvvm to the Medium lit (,der to prnote productivity of singl-cain IPAand to prevent pealing-off o the celIs from the walI of the container or the surface of beads, Furthermore, the present inventors found that productivity of sinle-chain IPA can be much Improved by increasing the osmotic pressure of the medium supplemunted.
with P-aminominthyi benzoic acid derivatives up to 350 milliosmoles or more/litre by using bicarbonate ion, and 4-em othe present invention, to tPA production according to the present invention can be carried out either in Parallel with the the cell growth or in tPA production process independently of the cell 00 0 growth.
o 0 Namely, the present invention relates to a method of producing human tissue type plasmlnogen activator, which !s Characterized in that a p-aminomethyl benZoic acid derivative is added to A cell Culture medium and that a panomlnethyl bonzoic acid de(rlvative i added to a tl’A prodUottla medium supplemented with a human tissue type ainoien activator Inducer after culitivation of the colJs to aa to Increase Productivity of singt-chaln tPA Purthermore, the present invention relates to a method of producing human Wt4aue type pswtnoogen atiLvatoro which la; characteriz.ed in that o.riemoti p’resure of the bovenentione’-d 2ii 5 ll IC(Iture medium or t M produlci ng medit um, both nUpplemesItd with 4 platlminomeothyl bon’,toOI Acid derivatiVe I l% inareased tip to 350O m!II I 1 osmno I Os or more/ I I re iby isi ng bicarbonoto Ion so as to greatly improve productivi ty of s iegle-chAin tPA.
Accord ing to the present inventijon, by adding ii inexpensive p-amliflomfethyl benzoic acid derivahives, in place of expensive aprotinin, which is conventionally used, to the cll culture medium or WPA producing roedium, productivity of slngle~-chain tPA can be improved and the peelineg-off of the cells -from the walls of a container or the surface of beads can b~e prevenlted. Furthermnore, duec to the rynergistic effect of bicarbonate ion and a p-aminomethyl, berizoic acid o oo derivativa added to the medium, prodAuctiVity of single-chain J a LtPA citn be highly improved.
o 0 Examples of p-aminomethyl boozoic acid derivatives W~ 0~ 0 On be used In the preint invention include p-aminomncthyl ben~olc ~d 3-methoxy-4-Ahlnomethyl ben~olo acid, 3- 4-,amlnoiiethyl benzolc acid, -nty-~mnmty beovn.
acid and 2-omrno-4-aminomethyl berntai actdk These paminomethyl bonzoic itcld derivakives are used talso In tho forwi, of eirter compndj01111,0 metal compwullds, o’g, IMal) I etal Ia or the mi ts thoreof~ e chlorldoea.
Ao oxamjule of thw I1A prodtiring ,,train to be ivsed in the Preownt Invention hT-18 coll line (J”‘pnwi~ fRitent Laid-Qpon Pub. No. 126978/1987) which is obtained b~r transforming mouso C-127 cells with the plasmid constrtatod wi th nsorti!onsg of a par t of 1the [IPV-derived p I sm Id comprising a DNA sequence In which a DNA sequence coding for, human tissue type plasmninogen activator derived from normal human cells is bound to ak human-derived metalloktalnelo promoter, of a part of pBfl.322 plasmid and of a DNA sequence necssary to stop transcription, Another examnple of the tPA producing ,;train is SV-21- M2.5 V( cell line (Japanese Patent [Laid-OQpen Pub. No.
126978/1987) which Is obtained by transforming C01O (Chinese hamster ovary) cells with the plasnild compriaing a DNA sequence, In Wh5 a DNA sequence coding -for human tissue type plasminogeni activator derived Irom. normal human cells I1S is bound to SV-40 early promoter and a DNA sequence Ooding QQ for dihydrofolate redtuctaseo and further by selecting cells carrying amplified genes on a medium supplemented with 000 methotrexate.
Naturallt any kinds of WEA Producing e11si for excample, thoso produced In combination wi th other toeatn ttuch as muta~tion or adaptation, or those transformed by viruges can be also used.
An eXample of the cell cul ture medium Ia the(- prseont invent ton i s a banal modilui sttpp 1 moented wi th fatall calIf serum in a a pproprlato amount (0 to to and turther nabs lances, necessa-,ry foz’ thle eel I grow ho a uch ar.
,-itr fac tan ts amno a1Lc I (is, sug~ar t and rl I ts if d aes re d.
F~urthermore, the tPA producing medium in the present invention Is, for examnple, a basal medium supplemented with fetal calf scrum in an appropriate amount (0 to 10 01and with tPA Inducing substances such Is zine, cadmium and sailt thereof at a concentration of I to 10 )iM, The basal medium in the present invention is a mediu~m comp~rising, for ex(ample, amino acids, vitamins and inorganic solts. Exampls of the basal medittm Include Duibecco’s Modified Eagle Medium (DMEM) (Ninsul Pharmacuticol Cot. Ltd.), 199 medium (Nissii Pharmaceuticals Co,, LACd) and E~agle’s Minimal Essent’Iit Medium.
According to the present Invention, the p-amjnornethYi benzoic acid derivatives are 4dded at conc(entions ran,01nf from 10, to 101M, more preferalbly from1 1Q0-3 to 10-2 M1 and either to a tIPA produ.cing medium, or alternatively to a cell culture meditUm to th~e caqo where a tPA producing mediurn 1s not used* ThUs, simplIy by’ addinrg p-inomethyl ben-?olc acid drivativeq to the medIum. pooling-off of the vollp. from the watt of a container, or Lhe qor~face of hoadn dutrint, ovultivation canti be prevnt(,(, and the prmltictivtt of~ angtle”chain WIA vain Io mprovod, withoat aoy conpliccAtod procediuro.
1’urthek moro, occordinge to th(* pnent, Iniwettton, by t noea i tle osmo t 1 o pressure u f the 4tboVemen t 1 oned eel oul ture medium or the tPA producing medium, tih suppilemornled wi th p-anminompethyl bonzoic acid derivatives, up to 3-50 mi 1liosmotes or more /I Itro using hicorbonato ion3, 4i Pee I Ing-o ff o f thte cel I sIo proven t ed, and wiuch I mprovemnt In productivity of Ginglo-chain tPA (:an be achieved.
Bicarbonate Ion used in the presvnt lnVention to Increase oqMotia pressure can be Provided as salts, e~g ,sodiurn bi rbonate (NalICQ1), or as eartion dioxide gas.
K 10 Accordine to tho present Invention* hicarbonate ion Is used tenera II Y in Pueh ain amoon t to manke the On of the osmnotic presnure attributed to the -,uppletneqted Inorati soaltot amikno avidto, vitamins and the like and a attributed to, ShO biearbonata ion# UOi mJ11loamoloo or F~or example# When the osmotio prooure Attrlhtted to I no rgan ic oal to~ I mlno aclda or v! tam no ao 28( Gti kkitaooa/1 Itrot bhi rbonate Ion to provide hurthvr Mitionmotvn or more/Ittre of osmotic ptwenue la WtQ4 a0 aO ttato total 3t50 militonmoten or, aror/1troo Fn order to control tho onmtic I cqUorO of the Wedima an abovvmentionced, for vempe, todilm hlczOronate (NAIKQ) al iic etr o of morn than ribout r I itroo Pr& eerably at 3 to 14 gil Itre In gnoral ly .”Wed to Hie Medinto* teitY of rifidi tin arid torim of bit arbonaito Ion are qPevted lepending on vult tvat~nn lhod5 Vned, F~or exaM;IN wh on a T- r I its.it r o I cr bo t, t 1 (11 1;be Ii j e i 3uaed, nodl 11M kiIca rbora t e i s pr e f ib IY add ed t o thite m edi am t o ma ke t Ito osmotic pressure of the meditin 360 to FYOG Cultivation of cells and production of WPA are proferably carried out in a carbon dioxde irs incubator in pither closed~ or open systems, Vurther, thc amount of carbon diox(ide iras dissolved in the medim uinder the Carbon dioxide gaq atmosphere Is at most about 0.0004 which corresponds to about I milikoamoette ‘Is teovrl Influence of the2 atmocpheria carbon dioxide -gas is negigiie ir the medium at PHf 6’s to the P11 rang;O- 0 usned In practice for cultivation* 0 0, Furthrmore# when cal tivant~of can he earried out In a 0 1 0 in n er o r a a r 1 b ic ar b on4 t 0o i041s p ro v i d by a plIy ig sodium bivarbotite toi the mediUm prior to cut tiVation and 4tt the srne time hy ,lowing ciarbon dtioxide gi; Irv the oysii, n a to maitin the total OsMotiC preouie In the lyotem to 500 mniltllofmolO5/1ttrO, Vl7urkher. p-amiiomphet- bon ‘oic a(id dervaVtjies mav he added to the hwal moedium, during prn Paratlonf or after Maklnpg te Moeditm hypertonic by blearbonake Ion, rear eel)1 ve ki’votion. any known :netliod; ‘Ireapiabe ForW exmplo the, followlng meothod van be vd Na me Iy t ani ap tr o )rit a t t unwat t el f IvIIa vre I noculttat Od i a a w e 4ium ta u 1 mvn t v witIh a t PA i n d I f i,I r ,d a a Hautx flask ctnd then IneUbated at an, ttpPr(p1itte temperature for an approprIateo time in a carbon dioxide gan incubator for tPA product ton in poal, lot wi th cel I growth.
Altornattvely, cells are inoculated in a median inl a oux flask~ ,And then allowed to grow ql; an appropriateO temperature for an, appropriate time In a carhon, dioxide igan Incuibotor. When the colia are e~rown to confluont, the medium Is replaced by tPA producing meilum, and then incubation to continucci in the carbon di1oxide gais incubatir at an aproprato tempera t tre for an appropriate time for tPA Production.
F~or example, when a 76-cm 2 Roux fla s InUsed, Oella are inoculated at the concentration of O0ll to ftP 1 O”/m1 and Incutbated at 37 0 C for 3 to 4 days for the growth In 16i parallel with tPA producetion.
AMternateiys for evimple, When A 75I-enV2 floujj fh~jqk Ia u-,edi colls ave ineetilatod at the conentraiton of I to 2, Incubatod aIt ,W)C for 3 to J daiyr for the vell growth. Then, the ineditim In ropkaced by It QIA produelvi, 1O mnedliti and the inv~ubution Ir; CorntiAlivd lat for I to :t dayt; for tfwA poduction, IEXAMP1L1t*I The( prenen tt Invvioln will be desacribed mao v(if teal ly by the tot lowitng FI’v~ien:Io”‘1 The e C! 11 ti i i f or t he t I A t) r o Iu(It o it w ir o to it th(abovaent ioned [iF 82,~ otrain f In 75i-cmV Rloux 4vI~,02( ml each of Dubeop Modi fied Eagle Medium qupplemvn ted with (o1 I serum which had been, heat- i nactIivaited fnd 10YI zAt 1ro chloride wais POWce. To eaceh mod ium, tpratIinkn, P- H4f ine thyl bcrvo ic acid or h~neIhcn4mnrioettq acdis a(dded inl the apecifo -aoa ihw (C fl)lt1)W in Yabl t.
IWeh culItuo med ium thus propared wasi nooiti ated wIq h abovemen tioned Col in at a corieWru tion of 1.0) U The tel In were incubated ttt 3i7″V for 4 dayno, Whou tho oa in wer g OI rown to coaf I iont f atiut 1 7 10 aO Ce I t/nl 01)R noncentrations, of sanoIce’chain tPA anid dolhittleht’ll tv#A In the culturec were determined by the ainlyn;in anribed betow hI&,*i IcuI are nhowi I n T,,Ab I v Vth method for the annlytks at snlt.efli tptilo andcoba hI n tPA In the 0111 Nre it; aq nl law”‘;.
R1E.1I3A Method.
MonoclIonaxl Oritthobd) e to ra~ “llateehi n WPA OV 21 Ainer i an DiagqonoteaIIo a nd Ionovlonal anft ihod io ea iingle-ehain WUA plus aovhle-ehin EIA IAtK.Ameiccu Diagntiva Co.) A re d iluted with a VO&Wuu W~iouton to t mirovn/m ,and 50( iuolcli terwi vwh of thv dl i~ted nliutt inAi is dispensed into the wel) at aa Fu LtIhA Plato NOJ Sweit Cn110h (4mAs Wrks). The plaett, v. lutwed W tavo fo hoari: atI room tempera tnue, and thien teI “W Ila WOt /4 we I I; s !ad iGoa t’da(4′ (21 tach, of the Wet 1s is wasihed it h a wash ing soltiton, anfd than fille 04with (4 blocking’ sotton. The pIli~e is alltowed to AM fador 2l0 minutes at room temparatture. 11 f ty i cr’o i1 tars Cach of 1000- -2000-f ol d(HI ouLed aaMpl v Go tu t 1ons and s tandard so Itit tann 1, 0, 1. A and 8 ng/ml )i a addedc in to ech of the wet I s, afl(J We1 I a to i a a Iowed to s tand fox hours” t) of~ the well tin again Washed wi th the washing, 101 sofutIAn, anld thaon an ant i-tVA rabbit tant ibody i odded into Oach well, S”10 oif the Wetlp Iil orn gI n Was had Wi.t tv het w”’10hi ne uo Imtiont and then 30 micuol I tars oY a 500-CAh1 di toted aol~tion of 40at an i-rabi Igo and 11a IaIino phopha Lan o J y coiat 0 “i gMa) I8 dded I nto oach IWeIt. I’he ‘kat o i a atltowvd to s Land for i hour ft ,tch of the wells, in agatin Wtinhed wi tk the wtdhnfo solutiooni, and theni 60 MIMI’o I tWry of a aUhntraty MIluton (p-n I tro phonyt phop4totf v 6~f rpg.4-m I .91gmal 1 added i 11t ~O eCh wO1 I I The kt V iqsA at lOWe toa stanl C~i o 8 ri In at w MY1 1 t f ty ml crol I1 tornl at a MN VOW~i nlu ,it t i n 11addod t o echd of the wells, to qntap on?,matltc a0tton Ah\bsorptlon ait 405l nriI road with tx ooretat ty ava Ii I h t o [I3, I $SA rnidor.
A memu uuri I nj, o e (I cr ,f ling’,0 o t n eadlnge of tnat'(0,,n and the LtPA ,nt tow, iit)hev “irqlens are (Ii detzermi ned, Calculations are made a follows.
Sinale-choin tPA content (mg/litr) Measurement for PAM-I Double-chain tPA content (mg/litre) t S Measuremnent for PAM-2 measurement for PAM-i 11. QuoIitatIve analysis by Immunoblotting Uoch cf the oul ture solutions is treated in a sample solotlon for elcltrophoresis with or without betamero0ptoethaool which reduces proteins in the samp)e. The G electrophorenis Is carried out according to the method of LaemmII 1970) After the electrophorestia proteins are 0 0 a lectrititahly tronnfrr’ed onto a nitroellulose filter by the method of ‘owbin et 4. (197/9), 1 0) NOn peciifie protein absorbing aitoo are aotturated o 0 with bovine ooruin albumin.
The Atltro 11UtoBL o filter la treated with primary antlbodile, I v. anti-tFAlhA ntbodies (for euampio, goait derlIved or rAbhb i t-cderived polYetontl intibodien or moinvederived monoclonal antibodlen), to atuvw to react with tPA on the n lt( otlulon filter.
Soonodtiry arbodtl end tire allowed to react with antitPA antibodlen and then allowed to react with alklltiOO}pha taue~X boun an I lbud I e” agtingt the acory G rn t Ihod I en’.
Color re’totin-n iF v’aried Oat ivr tlnr 0t 0 0
DI
a 0 ao oa 0000 a aaO ag a 0 000000 brorochioroindolyl phosphate, as a substrate for alkali phosphatase, which is dissolved in a solution containing nitrobluetetrazorium, so as Lo detect tPA or decomposed fractions or aggregates thereof on the nitrocellulose filter.
in the blotting with single-‘chain tPA, a major band at about 70 kd is obtained in both reduced and non-reduced samples, In the blolttn with double-chsin tPA, the major band at about 70 Rd simiLar to that with aingle-chaln tPA Is obtained in the non-reduced sample while in reduced qamptest bands at about 30 k4 and about 40 kd are obtained and the band at about 10 Rd ir not. The bands tund at about 70 kd 1 about 30 kd and About 40 Kd in the Immnrnootting a! thee reduced and non reduced somplos are cOMParod no 44 to 6 qualitatively este tht rte Of ;nteChain V’ to doubte-halj tPA in the At thouigh te ohimMobottInr 4nalyoli 1 a1 quitaive measu-emenn, it wos used to confirm the quantative data Conventonatly obtlained by rEISA, 20 As evidently shown in Table 1, in th, culture wM- It’ r tnenod with p-amtinorthyl honoic atId or It.
der i vat IV, Peel Inha-o f of the Lell waf rlativoly nainignIfit antnd 41nhti”chaie tP prAod tlon was War ImProv Par t IvtiIarl y wtth P-aminomethy beeOzoic* acid or Its 414 derivatve t, h Co n ratlon of 10D F1 or nutre E&et was comparable to or exceeditig, that with atrotitntn Table I Cone. Amuot of Rate Of Peelingsc- tPA~ dce.tPA* sa-(PA off*** (nit/I) 00 Control 118 52++ Aprotiniri 80 6.2 0.5 92 40 6.4 0.4 94 5, 0.6 g0 P-ftinomethyl 10- 7.2 0’3 96 benzoic, acid 1Q- 4 68 0.6 92 10-6 419 .8 3-thoxy–4- 10~’2 618 0.5 9s ami~nome tdiyI4 benzoia Aid IQ- 6.4 0.5o 92 0- 4.7 1,0 8n nSloglchotn tPA. V Eouble-chain MP.
4, In order of asceriding degree, of peeling-off.
The (-ell [ine unsed to rwample I wwo simllart 11sed, Tho cello were Inoculated at a eoncenrdrotloo ot 1.0 x 105 cal In/ml it) 20 pit each of blbeco-a M.odifled age MElW 5111p(Oiriontd with 10 X~ hit-inactivatd fetal cal nin 76ti l UOli flrnks, The P.011 l~wore IncUtlated at “1VA for 4 doiy%* when the (.c cells were grown to confluent (about 10 X 105 cells/ml), the medium was discarded and then replaced with 20 ml of the tPA producing medium having the same composition as described above except that zinc chloride at a concentration of 10 uM and respective additives shown in Table 2 were supplemented.
Incubation was continued in carboan dioxide Kas incubator at 37 0 C for 2 days. The concentrations of single-chain tPA and double-chain tPA In thte culture were determined as described in Example 1. Results are shown in Table 2.
As evidently shown In Table 2, in the cultuire supplemented with p-aminmethyl benzoic acid or its derivative, peeling-otf of the cells was relatively ftl Sinsigtnificant and single-chain tPA production was improved, Particularly, with p-‘aminomethyl benzoic acid or its derivative at a concentration of 10-) M or more, effect exceeded that with aprotinin.
4th 4 S4 Trable 2 Conc. Amount of Sc-LPA* dctPA* (mg/I Control 3.0 4.2 Aprotinin 80 8.8 1.0 (KIU/ml) 40 8,6 0.5 7.8 1.4 p-Aminornethy’j 102 9.8 0 benzoic acid 9.4l 0*4 1Qo 6 718 112 3-MothOXy-41- 10-2 9.2 0,4 ami nome thyl 1benzoic acid i0~ 8.7 100 (M4) to~ 6.8 2.0 Rate of Peeling sc-tPA of 42t+ 90 94 85 +4 100 96 86 96 77
C
C
C C C o C C CC C o 0) o o
CO
C COO 0 Cd CC o U C U C o o C CU 1 o CC C C C C UC
C
o U C CCI C U o o
C
U
*Sinple-chain W1A, Double-chain tPA.
O bserved with naked eyeo, (n order of oscnding degreve of peeling-‘off, C-xample 31 The cells uned for tPA production were those of 5V-;!1- M2.5 V7 cellI line which was obtained by trotioforminoi CHIO (Chinese haMster OVarYl cells WIth the plasinid compriSing a ONA at-quence In which a DNA aequepco coding for tPA was bound to SV-40 early promoter and a, DNA sequenct- coding for dihydrofo late reduatase, and (tirther by 1oeotUng the tt’ans()rmod (eI5 arrytoll amplified, renvs ort a medium strupp Ien ted wi th me tho t ro 1 The W A peodue t ion wta I1I
J
I carried out in the same manner as described in Example I except that zinc chloride was not added to the medium. The results are shown in Table 3. As evident in Table 3, peeling-off of the cells was relatively insignificant and single-chain PA production was improved in all the cases.
Particularly, with p-aminomethyl benzoic acid, the effect was remarkable, Table 3 Cone Amount of Hate of PeeaflJ9 so- tPA* dc- tPA S sC-tPA off (mg1/) (a C ontrol 1 2 1.3 49 Aprotin in 80 3.2 0..4 90 (KIVml) 40 3,41 0.3 93 20 2.7 0.4 860 p-Aminomethyl 10 2 38 0,2 94 bezolie acid io-, 3.8 03 92 to 3. 6 0.7 83 8-Mothoy’-4- 1o- 5 0.4 am I nome~ ;h:Y benzole acid 10″4 3.2 Q.5 87 tD6 2.5 0.8 76 Sinetle-cehain tPA. D Dauble-hnln tPA* SObservedwith naked eyoe.
In order of aneeinrh dwreoo pllO pels ff.
I, 4, 04
I
(000 o I 0i 4 4 4, 4, 4 *L 0* *0 00 0 000 4 44C 04 4*4 4 4444oo 44 H’xample ‘t S U The cells u00d for tPA prOdUction were those of hT-382 cell line which was obtained by transforming mouse 0-127 cells with the plasmid constructed with insertions of a part of the BPV-derivel plansmid comprising a DNA sequence in which a DNA sequence coding for tPA was bound to humanderived metaliothionein promoter, of a part of pflR322 plasmid and of a DNA sequence necessary to stop transcription, Int 7&1-Cm 2 Roux flasks, 20 ml each of DME~M medium, supplemented with 10 X. heat-inActivated fetal calf serum and 10 uM zinc chloride was poured. To each medium, aprotinin [(lU/mI) or p-aminomethyl benzolc acid at a concentration of 10-2N And furthermore sodium bicarbonate In specified Amounts Shown in Table 4 were nappleMented. Eanch of the medium thus prepared was Inoculated with the Abovementiooned cells at a concentration of 1.0 x tO~ cel Is/ml, The cells Were lncubaet In a 5 carbon dioxide i&ac Incubator At 37()!C for 4 day, When the cells wereQ arow,. to 0 ~con f I ent (bouItt 10 X 106 co- I1s/m cohcentrat Ion s of single-chain tPA in the indIvidual cuilturves were-( dotermined by the Method described above., The resulta are shown In Toble 4.
ZI ~~Measuitrement ts of osmotic pro-soure were made twine. simazu 4 Qsmometer+ After the 141MP’110i for’ tPA determination.
As OVIdentlY FlhoWn In ‘Ta’ble 4, when thoe Osmotia 2, r orenr.”ure of tho medium exceeded 3l00 mnlisae/ir~not wily in eea tPA prloduetion rate bat also over all tfPA production were improved. Furthermore, single-chain tPA production was more greatly improved in the medium supplemented with p-4mlnomethyl benzoic acid than in the medium supplemented with oprotinin.
Table 4
NAHCQ
3 Osmotic pressure Additive so-tPA* sc-tPA rate (M 1111 smo 1 es) Far AP 64 1000PAM1A*” 7,2 96 380 PAMBA 26,3 98 AP 14.3 0 450 PANDlA 281a 97 AP 7 d 10400 PAMBA 14.3 98 Sin tIgechBin WA SAprottoirt **P-Amloiomethyt 4enZolc acid Tha eCIn too HIA production wore those o, the nIn a0 atrain An Wsad In a mVx l 4t The cOlIc W&erO InOOUted at theo (O.nentEatloh. Of 1,0 x 10 5 ce IN.i/f In, 20 ml “I.Ch of DMNtM tat ppiem(Apted With 10 7. heatnactivatod d_ i cfa alf -I I r; serum in 75-cm 2 Roux flasks.
The cells were Incubated in a 5 V. carbon dioxide gas incubator at 37 0 C for 4 days, When the cellis were Krown to conelaent (10 x~ 10 5 cells/rnl), the medium was discarded anid then replaced with 20 ml ‘iach of the medium which had the sane composition as do-scribed 4bove excr pt that zinc chloride (10 pR) and further aprotinin (40 KIU/1ml) and aminomethyi tbenzQic acid (10″ aii well as sodium bicarbonate at the concentrat, ons specified In Table 4 were respectively aupplemeflte4., The colts were again incubated In a carbon dioxide ga inculbator at 37 0 C for 2 days for tPA production, The concentrations of tPA In tho individual C 0 culture were determlned at; described in E~xamiple 1. fler.0tS arc shown 1,n Tabe I 6 SIiIlar to E~xample 4# remorthabie Improvement in 00’~prodtlatIv Ity V a sIngleochaln tri was obrierved in the oultro io, whieh P-~aininomothYl ben;zotc acid Was riu ntd tn oamotic proescure was, intearsed, -7 TWO~ NaNIC03 ogsrnuU pressre Addc kitve s o LPA” sc-tPA rato AP** 8.6 00 1030PAMIIA**~* 918 AP 24.3J 88 3I80 PANE)A Wl82 9$ 450 PAtMflA 45.0Q 96 At’ 21.0 94 l040 44 4 inlte-chiii WA 0 4 Aprotfin 44:4 p-AmInoMothyl beo,c ACiA 444~ The ooli trntod for the tPA productionl were. Ctowv of SY*oll lttie th~j W~tp obtaJijod b)y tralisfornijo CII( (Chlno hamnoatt avaur?) ototIn wtth the phusmid compio.;iij, ct D WA qequen(ce JA whhoh a D)NA 1ecp4wtco codlog fo tPA wi; bood o the ooVr4( e -~?prvoInWr 00d a~ DNA, ngquenve vdinn for dlhdofolto roetr aind Lhon by avlooting ‘eLktt The tPA production~ iiat earrted out 14 the aamer riannit, iv rlooerkbodl in E.mupl 41 vx (P that thel~ n4 r m d I I 1 I (jq tJ “it 4 a zinc chloritle. Th” rslts are shown in Table G ItemovkablIo Ofe fcts Were, round no,” only in prodcte v! ty Of 3iingo-choin WPA bot also) in the~ rakI of n -lc al n t PA.
I nc) t, i I I UrCo ea Add i LIve
AV~**
MM [IA a a- 110 icotlA rato (mre/I) (1 31119~11 11.9 94 I (W 3100)
AP
PAMIIA
All~ PAMrIA
AP
VANUA~
81 1 0 ‘1t 7.
8$ 2 I 00 9 C) 92 $1olno1chain IA 4. Apro t In In p-AminthyJ botivutc 404~ Exampl~e 7 Thv volln u wed for the~ WA prodI~l I of wvi t ho tit th(e “‘341o dra f trined ill VX3IftIo 4 Th c 0″ VON~ Mot r Were I ntil a d at I tif vonv1entrati nn of 1.0 x Wk cell a/In inI ire 040h of DNIEM supplemnented With 10 VS heatiaIvnlc 1 e1 odi setr v I4 ,n tli t re 9 p ,n n or ti (top t aI op ti c t y o f LI)oP u .I,5 11 vin ectt c eqitp ped w it h stirring blaides, pit cleatrodes, DO electrodo,! and 4 pipe for itowlp ng gn. Sovd oe Is used had beeon cut tured in advtine In tho abovernt toned medium In a ro Iler hot tie, Incubation was vecrvied out Lit 37oC for 4 days. When the coil concont titIon rooohod 10 ceontin/mt, t he e’bovomentiIonod rncd iur wan 4 1 oerdol and rep I ated for LPA product ion, with I titre each of 1)MI* s ippionotd with 6 hee V I ec i Iyeted, total eel f norlirn, apratinin (410 ItImni) or P-41minomothyl, beonzaoe Avid (10’ and V.inc, ohlorlde, (10 JIM), In ovdvir to mel tiitin the enumotiv Pi~esuve, (if the meditrn eqns hoWn int ‘ajthh. Ic Ii ‘i IrhOn d OXI de tlt” a ocea 0001one II? 16, b~lown in to the hot t to pit Wa’s od i u todo Wtt, Nn0ll, V’ur thor no0 wwO mm 11 Ut noied% t t I PP?4 and Lte temopolrture at 3 P), Mod itp Ur hangv!O Were vl.( oitt onive a dary for Iid. n hu WPA fraot i on wvere reovvre d totally five timwO A oVideontly .thowil in Tahbi 7j stilurtv offoctr. an rohoWl I n Ex”Impto I wani OW(aerved whthe n tie(, p esnure wari eontrotlted Ity b~awilnie earholl dIoxtdo 1044 iLo he nedialw* Table 7 Osmot~ic Pronsre Addi Mevr (oil I I iosmoleni)
AP*
til l/- 113 G a 7.
(88 f 090) (88)~ 2 00 VANMA ~2 7111 1 10 6 4.G 33.4 (96) (97) 05 (96) (89 19:1) f 9 2 k Cox p 460 VVI I I A I 12 t 2 8 31i 2 M; -1 2 t t 9 8 Q’i 111 pX nm~thv hen’ni@ vfid -4

Claims (2)

4. A method according to claim 2, in which bicarbonate ion is added to said medium for production of human tissue type plasminogen activator to increase the osmotic pressure of the medium to 350 milliosmoles or more/litre, A method according to claim 2, 3 or 4, in which said p-aminomethyl bensoic acid derivative is p-aminomethyl bergoic acid, 6, A method according to claim 1, 2, 3 or 4, in which the concentration of said p-aminomethyl benzoic acid derivative in the medium is in the range of 10-4 to 10-1 M,

7. A method according to claim 1, substantially as hereinbefore described with reference to any one of the xampls, DAMED: 22 March 1,991 MITSUI TQATU$ CHEMICALS, tNCORPORATED $y their Patent Attorneyst PHItdLP$ OtMNDEP FITPATRC~t II~ S-27 KC: 7

AU34892/89A
1988-05-19
1989-05-17
Method for production of human tissue type plasminogen activator

Ceased

AU612837B2
(en)

Applications Claiming Priority (4)

Application Number
Priority Date
Filing Date
Title

JP12264488A

JP2648611B2
(en)

1988-05-19
1988-05-19

Production of human tissue-type plasminogen activator

JP63-122644

1988-05-19

JP63316118A

JP2718726B2
(en)

1988-12-16
1988-12-16

Production of human tissue-type plasminogen activator

JP63-316118

1988-12-16

Publications (2)

Publication Number
Publication Date

AU3489289A

AU3489289A
(en)

1989-11-23

AU612837B2
true

AU612837B2
(en)

1991-07-18

Family
ID=26459739
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU34892/89A
Ceased

AU612837B2
(en)

1988-05-19
1989-05-17
Method for production of human tissue type plasminogen activator

Country Status (10)

Country
Link

US
(1)

US5151359A
(en)

EP
(1)

EP0342931B1
(en)

AT
(1)

ATE108825T1
(en)

AU
(1)

AU612837B2
(en)

CA
(1)

CA1334288C
(en)

DE
(1)

DE68916857T2
(en)

DK
(1)

DK243589A
(en)

FI
(1)

FI98123C
(en)

NO
(1)

NO175541C
(en)

NZ
(1)

NZ229187A
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU614429B2
(en)

1988-10-04
1991-08-29
Mitsui Toatsu Chemicals Inc.
Method for production of human tissue type plasminogen activator

Families Citing this family (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5824552A
(en)

1994-02-18
1998-10-20
Teijin Limited
Medium for culturing animal cells

US5856179A
(en)

1994-03-10
1999-01-05
Genentech, Inc.
Polypeptide production in animal cell culture

US5705364A
(en)

1995-06-06
1998-01-06
Genentech, Inc.
Mammalian cell culture process

US5721121A
(en)

1995-06-06
1998-02-24
Genentech, Inc.
Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein

US6656466B1
(en)

1995-06-06
2003-12-02
Genetech, Inc.
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition

US20030087372A1
(en)

2001-06-13
2003-05-08
Genentech, Inc.
Methods of culturing animal cells and polypeptide production in animal cells

CA2829774C
(en)

2011-03-14
2019-09-24
National Research Council Of Canada
Method of viral production in cells

Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU4254189A
(en)

1988-10-04
1990-04-12

Mitsui Toatsu Chemicals Inc.

Method for production of human tissue type plasminogen activator

Family Cites Families (11)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3732146A
(en)

1970-12-22
1973-05-08
Behringwerke Ag
Process for the isolation of native, highly purified plasminogen

JPS59196824A
(en)

1983-04-21
1984-11-08
Kowa Co
Adsorption inhibitor

FR2548211B1
(en)

1983-06-29
1985-10-18
Choay Sa

PROCESS FOR PRODUCING TISSUE ACTIVATOR OF PLASMINOGEN AND ACTIVATOR OBTAINED THEREBY

US4554251A
(en)

1983-11-07
1985-11-19
The Ohio State University Research Foundation
Process and medium for culturing ant venom gland cells

GB8334499D0
(en)

1983-12-24
1984-02-01
Beecham Group Plc
Derivatives

US4724206A
(en)

1984-02-13
1988-02-09
Damon Biotech, Inc.
Protein production using hypertonic media

EP0163751B1
(en)

1984-06-05
1989-09-20
Asahi Kasei Kogyo Kabushiki Kaisha
Process for the preparation of a plasminogen activator

US4661453A
(en)

1984-06-19
1987-04-28
American Biogenetic Sciences, Inc.
Production of tissue plasminogen activator factor

US4661469A
(en)

1984-08-08
1987-04-28
Survival Technology, Inc.
t-PA composition capable of being absorbed into the blood stream and method of administration

JPS624233A
(en)

1985-07-01
1987-01-10
Toyobo Co Ltd
Production of histogenous plasminogen activator

US4960702A
(en)

1985-09-06
1990-10-02
Codon
Methods for recovery of tissue plasminogen activator

1989

1989-05-05
US
US07/347,649
patent/US5151359A/en
not_active
Expired – Fee Related

1989-05-09
CA
CA000599119A
patent/CA1334288C/en
not_active
Expired – Fee Related

1989-05-16
DE
DE68916857T
patent/DE68916857T2/en
not_active
Expired – Fee Related

1989-05-16
EP
EP89304944A
patent/EP0342931B1/en
not_active
Expired – Lifetime

1989-05-16
AT
AT89304944T
patent/ATE108825T1/en
not_active
IP Right Cessation

1989-05-17
AU
AU34892/89A
patent/AU612837B2/en
not_active
Ceased

1989-05-17
FI
FI892358A
patent/FI98123C/en
not_active
IP Right Cessation

1989-05-18
NO
NO891995A
patent/NO175541C/en
unknown

1989-05-18
NZ
NZ229187A
patent/NZ229187A/en
unknown

1989-05-19
DK
DK243589A
patent/DK243589A/en
not_active
Application Discontinuation

Patent Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU4254189A
(en)

1988-10-04
1990-04-12
Mitsui Toatsu Chemicals Inc.
Method for production of human tissue type plasminogen activator

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU614429B2
(en)

1988-10-04
1991-08-29
Mitsui Toatsu Chemicals Inc.
Method for production of human tissue type plasminogen activator

Also Published As

Publication number
Publication date

EP0342931A1
(en)

1989-11-23

NO175541B
(en)

1994-07-18

US5151359A
(en)

1992-09-29

CA1334288C
(en)

1995-02-07

NO891995L
(en)

1989-11-20

AU3489289A
(en)

1989-11-23

NZ229187A
(en)

1991-12-23

DE68916857D1
(en)

1994-08-25

NO891995D0
(en)

1989-05-18

NO175541C
(en)

1994-10-26

FI98123C
(en)

1997-04-25

DK243589A
(en)

1989-11-20

FI98123B
(en)

1997-01-15

DE68916857T2
(en)

1994-11-10

EP0342931B1
(en)

1994-07-20

ATE108825T1
(en)

1994-08-15

FI892358A0
(en)

1989-05-17

DK243589D0
(en)

1989-05-19

FI892358A
(en)

1989-11-20

Contact information